Withdrawing antiepileptic drugs in seizure-free patients: What are the cognitive benefits?: Commentary

Nature Clinical Practice Neurology

Volumn 3, Issue 4, 2007, Pages 194-195

  Perucca, Emilio ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; PHENYTOIN; PLACEBO; VALPROIC ACID;

CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MEDICAL DECISION MAKING; NEUROLOGIC EXAMINATION; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; QUALITY OF LIFE; RECURRENCE RISK; REFUSAL TO PARTICIPATE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEIZURE; SHORT SURVEY; STUDENT T TEST; TREND STUDY; WELLBEING;

EID: 34247223223     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0449     Document Type: Short Survey

References (5)

1. Ortinski P and Meador KJ (2004) Cognitive side effects of antiepileptic drugs. Epilepsy Behav 5 (Suppl 1): S60-S65
2. Cochrane HC et al. (1998) Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: A systematic review of methodology and reporting standards. Epilepsia 30: 1088-1097
3. Chadwick D and Privitera M (2006) How skeptical should we be about industry-sponsored studies? Neurology 67: 378-379
4. Sillanpaa A and Schmidt D (2006) Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: A long-term population based study of childhood-onset epilepsy. Epilepsy Behav 8: 713-719
5. Specchio LM and Beghi E (2004) Should antiepileptic drugs be withdrawn in seizure-free patients? Drugs 18: 201-212